No, they are implementing changes which will greatly improve the speed of the trial due to endpoint change from OS to ORR and efficacy into more patient situations. They also know who will respond based on DC characteristics created BEFORE actual treatment begins. If you had read the document you would notice the changes being made and that the product and manufacturing are ready but the wording of the submission is being changed to take advantage of recent regulatory pathway changes. By doing this they are staying out front of research and regulatory changes which big pharma and others were hoping to get a leg up with while they hoped NWBO would make the mistake of starting too early. That didn’t happen!; ). Best wishes.
Market Data 
Markets 
AI
